4-methoxymethyl[2.2]paracyclophane | 435346-97-7

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 4-methoxymethyl[2.2]paracyclophane
• 英文别名: 5-(Methoxymethyl)tricyclo[8.2.2.24,7]hexadeca-1(13),4,6,10(14),11,15-hexaene；5-(methoxymethyl)tricyclo[8.2.2.24,7]hexadeca-1(13),4,6,10(14),11,15-hexaene
• CAS: 435346-97-7
• 化学式: C₁₈H₂₀O
• 分子量: 252.356
• InChiKey: MBCYITNDEOGKPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对二甲苯二聚体 在 bis(dimethylamino)naphthalene 氢氧化钾 、 lithium aluminium tetrahydride 、 三氯化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 3.0h， 生成 4-methoxymethyl[2.2]paracyclophane
  参考文献：
  名称：

  新型聚对二甲苯：具有定制的化学和光学性质的薄膜

  摘要：

  化学气相沉积聚合用于制备具有不同化学和光学性质的聚对二甲苯亚微米薄膜。该聚合物是由13种不同的[2.2]对环环烷制备的，它们具有不同的取代度和官能度，包括羟基，甲氧基，氨基，三氟甲磺酸酯或三氟乙酰基。聚（p-二甲苯）与预期的化学结构相符，正如X射线光电子能谱，显微分析和反射吸收红外光谱所证实的那样。对于所有聚合物，已报道了基本光学性质，例如非凡和寻常的折射率，并揭示了涂层的光学各向异性。实验数据与单轴柯西色散模型生成的数据很好地相关。此外，观察到折射率与官能团的电子性质之间明显的相关性。类似地，光学双折射取决于官能团的性质，因为在报道的聚对二甲苯中发现了光学双折射的显着变化。

  DOI：

  10.1021/ma011769e

文献信息

• Ether Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239920A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  提供了有关制备抑制补体因子D的化合物、使用方法和制备过程，所述化合物包括具有式I的化合物，或其药用可接受的盐或组合物，其中A组上的R12或R13是醚（R32）。本文描述的抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联，并减少因子D调节经典和凝集素补体途径的能力。本文描述的因子D抑制剂能够减少过度激活的补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• Chemical film on substrate and method of forming the same, method of forming paracyclophane containing functional ground with disulfide bond
  申请人：MAY-HWA ENTERPRISE CORPORATION

  公开号：US10246412B2

  公开（公告）日：2019-04-02

  The present invention provides a method of forming paracyclyophane containing disulfide functional group. The paracyclophane is prepared by adding 3,3′-dithiodipropionic acid (DPDPA) and N-ethyl-N′-(3-(dimethylamino)propyl)carbodiimide (EDC) into 4-aminomethyl [2,2] paracyclophane. The present invention further provides a chemical film and a method of forming the same. The chemical film contains poly-p-xylylene with disulfide functional group and is formed on a substrate by a chemical vapor deposition process.

  本发明提供了一种形成含有二硫官能团的对二环氧乙烷的方法。将 3,3′-二硫代二丙酸（DPDPA）和 N-乙基-N′-(3-(二甲基氨基)丙基)碳二亚胺（EDC）加入 4-氨基甲基[2,2]对二环氧乙烷中制备对二环氧乙烷。本发明进一步提供了一种化学薄膜及其形成方法。该化学薄膜含有二硫官能团的聚对二甲苯，通过化学气相沉积工艺在基底上形成。
• Method of forming paracyclophane containing functional group with disulfide bond
  申请人：MAY-HWA ENTERPRISE CORPORATION

  公开号：US10336692B2

  公开（公告）日：2019-07-02

  The present invention provides a method of forming paracyclyophane containing disulfide functional group. The paracyclophane is prepared by adding 3,3′-dithiodipropionic acid (DPDPA) and N-ethyl-N′-(3-(dimethylamino)propyl)carbodiimide (EDC) into 4-aminomethyl [2,2] paracyclophane. The present invention further provides a chemical film and a method of forming the same. The chemical film contains poly-p-xylylene with disulfide functional group and is formed on a substrate by a chemical vapor deposition process.

  本发明提供了一种形成含有二硫官能团的对二环氧乙烷的方法。将 3,3′-二硫代二丙酸（DPDPA）和 N-乙基-N′-(3-(二甲基氨基)丙基)碳二亚胺（EDC）加入 4-氨基甲基[2,2]对二环氧乙烷中制备对二环氧乙烷。本发明进一步提供了一种化学薄膜及其形成方法。该化学薄膜含有二硫官能团的聚对二甲苯，通过化学气相沉积工艺在基底上形成。
• MULTIFUNCTIONAL CVD COATINGS
  申请人：Lahann Joerg

  公开号：US20080269456A1

  公开（公告）日：2008-10-30

  Multifunctional reactive polymers created by chemical vapor deposition (CVD) and methods of making such polymeric systems are provided. Such polymers provide multifunctional surfaces which can present two or more different molecules (e.g. biological ligands) in controlled ratios. Polymers may include compositional gradients allowing attached ligands to be presented as continuous gradients across a surface. The polymer compositions are modularly designable and applicable to a wider range of applications, including biomedical devices and diagnostic systems.
• ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20160362433A1

  公开（公告）日：2016-12-15

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.